The lowered price target from $3.75 to $3 by Raymond James analyst Jayson Bedford may have a neutral impact on BrainsWay's stock price in the short term. The Outperform rating is maintained, indicating that the analyst still believes the stock will outperform the market. However, the reduced price target may cause some investors to reevaluate their positions.